The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Increased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort
Open accessAbstract
OBJECTIVE: The authors previously observed an increase in striatal dopamine transmission following amphetamine challenge in 15 untreated patients with schizophrenia compared to 15 matched healthy subjects. The purpose of this study was to replicate this finding in a new cohort of schizophrenic patients and healthy subjects. METHOD: Fifteen patients with schizophrenia and 15 healthy subjects matched for age, gender, ethnicity, and parental socioeconomic status were recruited for this study. Patients fulfilled DSM-IV criteria for schizophrenia, had no history of alcohol or substance abuse or dependence, and were neuroleptic free for a minimum of 21 days. Amphetamine-induced dopamine release was assessed by the reduction in dopamine D2 receptor availability induced by an acute amphetamine challenge (0.3 mg/kg, intravenous bolus). Reduction in D2 receptor availability was measured with single photon emission computed tomography and the D2 receptor radiotracer [123I]IBZM. RESULTS: No differences were observed between patients with schizophrenia and the comparison group in D2 receptor availability at baseline. Patients with schizophrenia exhibited a significantly larger reduction in D2 receptor availability following acute amphetamine challenge than the comparison group. In this study, the effect size was smaller than in the first study. Excess dopamine release following amphetamine was associated with transient emergence or worsening of positive symptoms. CONCLUSIONS: In this new cohort of subjects the authors replicated their initial observation of a dysregulation of striatal dopamine release in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Four Factor Index of Social Status
Paschou, R. (1975) · Cited by 6,989
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Self-citationBreier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
Zetterström, T., Sharp, T., Marsden, C. A., & Ungerstedt, U. (1983) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1983.tb00893.x · Cited by 616
Farde, L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810150013003 · Cited by 530
Kuczenski, R., & Segal, D. (1989) · The Journal of Neuroscience · doi:10.1523/jneurosci.09-06-02051.1989 · Cited by 398
SPECT imaging of striatal dopamine release after amphetamine challenge.
Laruelle, M. A., Abi‐Dargham, A., van Dyck, C. H., Rosenblatt, W., Zea‐Ponce, Y., Zoghbi, S. S., Baldwin, R. M., Charney, D. S., Hoffer, P. B., & Kung, H. F. (1995) · PubMed · Cited by 333
Self-citationMicrodialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates
Laruelle, M., Iyer, R. N., Al-Tikriti, M. S., Zea-Ponce, Y., Malison, R., Zoghbi, S. S., Baldwin, R. M., Kung, H. F., Charney, D. S., Hoffer, P. B., et al. (1997) · Synapse · doi:10.1002/(sici)1098-2396(199701)25:1<1::aid-syn1>3.0.co;2-h · Cited by 265
Self-citation
Cited by
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
The neuropathology of schizophrenia
Harrison, P. J. (1999) · Brain · doi:10.1093/brain/122.4.593 · Cited by 1,677
McCutcheon, R. A., Reis Marques, T., & Howes, O. D. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.3360 · Cited by 1,481
Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
Stephan, K. E., Friston, K. J., & Frith, C. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn176 · Cited by 1,134
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
Self-citationJauhar, S., Johnstone, M., & McKenna, P. J. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01730-x · Cited by 996
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
Self-citationImaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review
Laruelle, M. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200003000-00001 · Cited by 944
Self-citationA pathophysiological framework of hippocampal dysfunction in ageing and disease
Small, S. A., Schobel, S. A., Buxton, R. B., Witter, M. P., & Barnes, C. A. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3085 · Cited by 926
Chumakov, I., Blumenfeld, M., Guerassimenko, O., Cavarec, L., Palicio, M., Abderrahim, H., Bougueleret, L., Barry, C., Tanaka, H., La Rosa, P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412499 · Cited by 829
Prefrontal neurons and the genetics of schizophrenia
Weinberger, D. R., Egan, M. F., Bertolino, A., Callicott, J. H., Mattay, V. S., Lipska, B. K., Berman, K. F., & Goldberg, T. E. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01252-5 · Cited by 741
Increased dopamine transmission in schizophrenia: relationship to illness phases
Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., & Innis, R. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00067-0 · Cited by 715
Self-citationGlutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Interactions Between Monoamines, Glutamate, and GABA in Schizophrenia: New Evidence
Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M., & Carlsson, M. L. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.237 · Cited by 688
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., Weinberger, D. R., & Berman, K. F. (2002) · Nature Neuroscience · doi:10.1038/nn804 · Cited by 652
To Model a Psychiatric Disorder in Animals Schizophrenia As a Reality Test
Lipska, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00137-8 · Cited by 650
Half a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.006 · Cited by 617
Self-citationDopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Self-citationIncreased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
Self-citationMartinez, D., Slifstein, M., Broft, A., Mawlawi, O., Hwang, D.-R., Huang, Y., Cooper, T., Kegeles, L., Zarahn, E., Abi-Dargham, A., et al. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000048520.34839.1a · Cited by 569
Self-citationA neurobiological basis for substance abuse comorbidity in schizophrenia
Chambers, R. A., Krystal, J. H., & Self, D. W. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01134-9 · Cited by 548
Self-citationTargeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544
“Increased subcortical dopaminergic activity in schizophrenia has been confirmed by the finding that AMPH-induced striatal dopamine release, as measured by displacement of [(11)C] raclopride or [(123)I] IBZM binding to D2 dopamine receptors, is increased in a subset of patients with schizophrenia and correlated with th…”
MethodResultKellendonk, C., Simpson, E. H., Polan, H. J., Malleret, G., Vronskaya, S., Winiger, V., Moore, H., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.023 · Cited by 520
Food and Drug Reward: Overlapping Circuits in Human Obesity and Addiction
Volkow, N. D., Wang, G. J., Fowler, J. S., Tomasi, D., & Baler, R. (2011) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2011_169 · Cited by 525
The Pathophysiology of Schizophrenia Disorders: Perspectives From the Spectrum
Siever, L. J., & Davis, K. L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.398 · Cited by 509
van Winkel, R., Stefanis, N. C., & Myin-Germeys, I. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn101 · Cited by 489
Zuckerman, L., Rehavi, M., Nachman, R., & Weiner, I. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300248 · Cited by 485
A Possible Role for the Striatum in the Pathogenesis of the Cognitive Symptoms of Schizophrenia
Simpson, E. H., Kellendonk, C., & Kandel, E. (2010) · Neuron · doi:10.1016/j.neuron.2010.02.014 · Cited by 478
Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies
Laruelle, M., & Abi-Dargham, A. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300405 · Cited by 461
Self-citationInflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 442
Glutamate, Dopamine, and Schizophrenia: From Pathophysiology to Treatment
LARUELLE, M., KEGELES, L. S., & ABI‐DARGHAM, A. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.063 · Cited by 437
Self-citationKantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 396
Weiner, I. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1313-x · Cited by 391
Kapur, S., & Remington, G. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Kegeles, L. S., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J. J., Van Heertum, R. L., Cooper, T. B., Carlsson, A., & Laruelle, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00976-8 · Cited by 377
Self-citationNeurobiology of Dopamine in Schizophrenia
Guillin, O., Abi‐Dargham, A., & Laruelle, M. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78001-1 · Cited by 365
“Striatal D2 receptor density in schizophrenia has been extensively studied with PET and SPECT imaging (Abi-Dargham et al. 1998b; Abi-Dargham et al. 2000c; Blin et al. 1989; Breier et al. 1997a; Crawley et al. 1986; Hietala et al. 1994b; Knable et al. 1997; Laruelle et al. 1996a; Martinot et al.…”
BackgroundMethodSelf-citationDo we still believe in the dopamine hypothesis? New data bring new evidence
Abi-Dargham, A. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004110 · Cited by 361
Self-citationLaruelle, M. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00054-5 · Cited by 358
Self-citationDopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience
Kesby, J., Eyles, D., McGrath, J., & Scott, J. (2018) · Translational Psychiatry · doi:10.1038/s41398-017-0071-9 · Cited by 352
Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review
Stone, J. M., Morrison, P. D., & Pilowsky, L. S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073126 · Cited by 348
The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia
Tseng, K. Y., Chambers, R. A., & Lipska, B. K. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.11.039 · Cited by 341
Linking nucleus accumbens dopamine and blood oxygenation
Knutson, B., & Gibbs, S. E. B. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0686-7 · Cited by 337
“For instance, radioligand PET research indicates that unmedicated schizophrenics show excessive and chronic dopamine release in the NAcc (Abi-Dargham et al. 1998).”
BackgroundWaltz, J. A., & Gold, J. M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.010 · Cited by 331
Waltz, J. A., Frank, M. J., Robinson, B. M., & Gold, J. M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.042 · Cited by 327
Under the curve: Critical issues for elucidating D1 receptor function in working memory
Williams, G. V., & Castner, S. A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.09.028 · Cited by 326
Catechol- O -Methyltransferase Genotype and Dopamine Regulation in the Human Brain
Akil, M., Kolachana, B. S., Rothmond, D. A., Hyde, T. M., Weinberger, D. R., & Kleinman, J. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02008.2003 · Cited by 325
Cannabis, the mind and society: the hash realities
Murray, R. M., Morrison, P. D., Henquet, C., & Forti, M. D. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2253 · Cited by 322
Stimulant psychosis: systematic review
Curran, C., Byrappa, N., & McBride, A. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.185.3.196 · Cited by 318
McCutcheon, R., Beck, K., Jauhar, S., & Howes, O. D. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx180 · Cited by 305
Diverse Psychotomimetics Act Through a Common Signaling Pathway
Svenningsson, P., Tzavara, E. T., Carruthers, R., Rachleff, I., Wattler, S., Nehls, M., McKinzie, D. L., Fienberg, A. A., Nomikos, G. G., & Greengard, P. (2003) · Science · doi:10.1126/science.1089681 · Cited by 314
Modeling madness in mice: one piece at a time
Arguello, P. A., & Gogos, J. A. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.023 · Cited by 309
Boileau, I., Dagher, A., Leyton, M., Gunn, R. N., Baker, G. B., Diksic, M., & Benkelfat, C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.12.1386 · Cited by 305
The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking
MONTI, J., & JANTOS, H. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00929-1 · Cited by 302
Social brain dysfunctions in schizophrenia: A review of neuroimaging studies
Brunet-Gouet, E., & Decety, J. (2006) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2006.05.001 · Cited by 299
Neurotransmitter interactions in schizophrenia–therapeutic implications
Carlsson, A., Waters, N., & Carlsson, M. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00117-1 · Cited by 298
Schizophrenia: Etiology and Course
Walker, E., Kestler, L., Bollini, A., & Hochman, K. M. (2004) · Annual Review of Psychology · doi:10.1146/annurev.psych.55.090902.141950 · Cited by 297
Pathway-Specific Dopamine Abnormalities in Schizophrenia
Weinstein, J. J., Chohan, M. O., Slifstein, M., Kegeles, L. S., Moore, H., & Abi-Dargham, A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.03.2104 · Cited by 297
Self-citationTowards a muscarinic hypothesis of schizophrenia
Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., & Dean, B. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001924 · Cited by 291
Lindström, L. H., Gefvert, O., Hagberg, G., Lundberg, T., Bergström, M., Hartvig, P., & Långström, B. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00109-2 · Cited by 284
Schizophrenia: from phenomenology to neurobiology
Wong, A. H. C., & Van Tol, H. H. M. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(03)00035-6 · Cited by 280
Increased stress-induced dopamine release in psychosis
Mizrahi, R., Addington, J., Rusjan, P. M., Suridjan, I., Ng, A., Boileau, I., Pruessner, J. C., Remington, G., Houle, S., & Wilson, A. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.10.009 · Cited by 277
Elevated Intrasynaptic Dopamine Release in Tourette’s Syndrome Measured by PET
Singer, H. S., Szymanski, S., Giuliano, J., Yokoi, F., Dogan, A. S., Brasic, J. R., Zhou, Y., Grace, A. A., & Wong, D. F. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1329 · Cited by 259
Phenotype of schizophrenia: a review and formulation
Tamminga, C. A., & Holcomb, H. H. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001563 · Cited by 262
Striatal Presynaptic Dopamine in Schizophrenia, Part II: Meta-Analysis of [18F/11C]-DOPA PET Studies
Fusar-Poli, P., & Meyer-Lindenberg, A. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr180 · Cited by 262
Acetylcholine–Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders
Lester, D. B., Rogers, T. D., & Blaha, C. D. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00142.x · Cited by 259
Egerton, A., Chaddock, C. A., Winton-Brown, T. T., Bloomfield, M. A. P., Bhattacharyya, S., Allen, P., McGuire, P. K., & Howes, O. D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.017 · Cited by 253
Dopaminergic basis of salience dysregulation in psychosis
Winton-Brown, T. T., Fusar-Poli, P., Ungless, M. A., & Howes, O. D. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2013.11.003 · Cited by 231
Dopamine hypothesis of schizophrenia: Making sense of it all
Toda, M., & Abi-Dargham, A. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0041-7 · Cited by 235
Self-citationBrain SPECT Imaging of Amphetamine-Induced Dopamine Release in Euthymic Bipolar Disorder Patients
Anand, A., Verhoeff, P., Seneca, N., Zoghbi, S. S., Seibyl, J. P., Charney, D. S., & Innis, R. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1108 · Cited by 222
Self-citationReduced prefrontal-parietal effective connectivity and working memory deficits in schizophrenia
Deserno, L., Sterzer, P., Wüstenberg, T., Heinz, A., & Schlagenhauf, F. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3405-11.2012 · Cited by 214
Abi-Dargham, A., van de Giessen, E., Slifstein, M., Kegeles, L. S., & Laruelle, M. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.12.007 · Cited by 213
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205
Self-citationHowes, O. D., Williams, M., Ibrahim, K., Leung, G., Egerton, A., McGuire, P. K., & Turkheimer, F. (2013) · Brain · doi:10.1093/brain/awt264 · Cited by 198
“…Kumakura et al., 2007; Bose et al., 2008; Howes et al., 2009b; Nozaki et al., 2009; Shotbolt et al., 2011; Demjaha et al., 2012), and elevated baseline and stimulated striatal dopamine levels (Laruelle et al., 1996; Breier et al., 1997; Abi-Dargham et al., 1998, 2000, 2009; Mizrahi et al., 2012).”
Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179
Self-citationElman, I., Borsook, D., & Lukas, S. E. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301051 · Cited by 169
Sleep and circadian rhythm dysregulation in schizophrenia
Monti, J. M., BaHammam, A. S., Pandi-Perumal, S. R., Bromundt, V., Spence, D. W., Cardinali, D. P., & Brown, G. M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.021 · Cited by 157
Current perspectives on incentive salience and applications to clinical disorders
Olney, J. J., Warlow, S. M., Naffziger, E. E., & Berridge, K. C. (2018) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2018.01.007 · Cited by 157
“For example, higher dopamine metabolite levels in striatum is associated with greater positive symptoms [108], and levels of released striatal dopamine are almost doubled in schizophrenia compared to controls [109,110].”
BackgroundBoksa, P., & El-Khodor, B. F. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(03)00012-5 · Cited by 157
Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
Sarter, M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi006 · Cited by 153
Anand, A., Barkay, G., Dzemidzic, M., Albrecht, D., Karne, H., Zheng, Q.-H., Hutchins, G. D., Normandin, M. D., & Yoder, K. K. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00936.x · Cited by 139
Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans
Riccardi, P., Li, R., Ansari, M. S., Zald, D., Park, S., Dawant, B., Anderson, S., Doop, M., Woodward, N., Schoenberg, E., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300916 · Cited by 134
Self-citationDopamine D2 receptor availability and amphetamine-induced dopamine release in unipolar depression
Parsey, R. V., Oquendo, M. A., Zea-Ponce, Y., Rodenhiser, J., Kegeles, L. S., Pratap, M., Cooper, T. B., Van Heertum, R., Mann, J. J., & Laruelle, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01089-7 · Cited by 133
Self-citationWaltz, J. A., Frank, M. J., Wiecki, T. V., & Gold, J. M. (2011) · Neuropsychology · doi:10.1037/a0020882 · Cited by 132
Abi-Dargham, A., Kegeles, L. S., Zea-Ponce, Y., Mawlawi, O., Martinez, D., Mitropoulou, V., O'Flynn, K., Koenigsberg, H. W., Van Heertum, R., Cooper, T., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.018 · Cited by 128
Self-citationMechanisms of Working Memory Impairment in Schizophrenia
Van Snellenberg, J. X., Girgis, R. R., Horga, G., van de Giessen, E., Slifstein, M., Ojeil, N., Weinstein, J. J., Moore, H., Lieberman, J. A., Shohamy, D., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.02.017 · Cited by 123
Self-citationAn integrative framework for perceptual disturbances in psychosis
Horga, G., & Abi-Dargham, A. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0234-1 · Cited by 103
Self-citationTracing the development of psychosis and its prevention: what can be learned from animal models
Piontkewitz, Y., Arad, M., & Weiner, I. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.019 · Cited by 108
Willeit, M., Ginovart, N., Graff, A., Rusjan, P., Vitcu, I., Houle, S., Seeman, P., Wilson, A. A., & Kapur, S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301400 · Cited by 107
Mizrahi, R., Kenk, M., Suridjan, I., Boileau, I., George, T. P., McKenzie, K., Wilson, A. A., Houle, S., & Rusjan, P. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.347 · Cited by 101
Sarter, M., Bruno, J. P., & Parikh, V. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301285 · Cited by 100
How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?
Kondziella, D., Brenner, E., Eyjolfsson, E. M., & Sonnewald, U. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2006.09.006 · Cited by 83
Aguilar-Valles, A., Flores, C., & Luheshi, G. N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010967 · Cited by 72
“symptoms of the disorder [81–84].”
An Overview of the Association between Schizotypy and Dopamine
Mohr, C., & Ettinger, U. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00184 · Cited by 63
Shi, S., Leites, C., He, D., Schwartz, D., Moy, W., Shi, J., & Duan, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.535203 · Cited by 61
Striatal dopamine, reward, and decision making in schizophrenia
Deserno, L., Schlagenhauf, F., & Heinz, A. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.1/ldeserno · Cited by 58
Castner, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00080-9 · Cited by 54
“Moreover, this interpretation could help to explain the differences between the findings in the present experiment for sensitized monkeys and those previously reported for schizophrenics (Abi-Dargham et al. 1998; Laruelle et al. 1996; Breier et al. 1997).”
BackgroundResultJoyce, J. N. (2001) · Synapse · doi:10.1002/syn.1035 · Cited by 47
“Recent in vivo imaging studies have confirmed the original hypothesis that there is elevated DA levels in schizophrenic patients leading to a hyperdopaminergic tone (Abi-Dargham et al., 1998; Breier et al., 1997; Laruelle, 2000).”
Background
Metadata
- Authors
- Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R. M., Seibyl, J. P., Bowers, M., van Dyck, C. H., Charney, D. S., Innis, R. B., & Laruelle, M.
- Venue
- American Journal of Psychiatry
- Published
- 1998-06-01
- Volume
- 155
- Issue
- 6
- Pages
- 761-767
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1856679114
- Cited by
- 803
- References
- 17
- FWCI
- 18.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.